Status:
UNKNOWN
Type 1 Multiple Endocrine Neoplasia Cohort Study
Lead Sponsor:
Centre Hospitalier Universitaire Dijon
Conditions:
Type 1-Multiple Endocrine Neoplasia Syndrome
Eligibility:
All Genders
Brief Summary
Type 1 - Multiple Endocrine Neoplasia syndrome (MEN1,) is an autosomal dominant disorder secondary to MEN1 mutations that predisposes carriers to endocrine tumors. The MEN1 gene located on chromosome ...
Eligibility Criteria
Inclusion
- Patients with MEN1 according to the Gubbio criteria :
- Patients with a MEN1 mutation and presenting at least one of the following symptomatic or silent lesions: pHPT or pancreatic or duodenal endocrine tumor
- Pituitary tumor
- Adrenal tumor
- th-NET
- br-NET
- And gastric enterochromaffin-like tumor (ECLoma).
- Patients belonging to a known MEN1 family (at least one first-degree relative affected) and presenting at least one of the aforementioned lesions.
- Patients without positive genetic testing or a family background presenting at least two of the three major MEN1 lesions (pHPT, pancreatic, or duodenal endocrine tumor, pituitary tumor).:
Exclusion
Key Trial Info
Start Date :
January 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03262129
Start Date
January 1 2012
End Date
December 1 2020
Last Update
August 25 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Dijon Bourgogne
Dijon, France, 21079